Loratadim

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Loratadim

Property Description
Active ingredient Loratadine (INN)
Form Tablet, Syrup, Oral solution, Orally disintegrating tablet
Pharmacological class Second-generation H1-receptor antagonist
Common use Relief of general allergic symptoms
Origin Synthetic (Tricyclic compound)

What Type of Medicine is Loratadim?

Loratadim is a trade name for a medicinal product containing the active constituent Loratadine (INN). Pharmacologically, it is classified as a second-generation H1-receptor antagonist. This classification is clinically recognized for providing effective antihistamine action with a reduced risk of the sedative effects often associated with older generations. Structurally, Loratadine is a synthetic compound, identified as a tricyclic compound and piperidine derivative. This specific structure dictates its function as a non-sedating agent.


Composition and Available Forms of Loratadim

Loratadim is prepared for oral and systemic use, meaning the medication must be absorbed into the bloodstream. The drug is manufactured in several dosage forms, including the familiar solid tablet, as well as liquid preparations like syrup and oral solution, and the specialized orally disintegrating tablet. The composition is centered on the Loratadine molecule combined with necessary solid excipients for tablets or an aqueous solution base for the liquid forms, ensuring stable and accessible delivery to a broad patient group.


What is the General Purpose of Loratadim?

The general purpose of Loratadim is to relieve general allergic symptoms by interrupting the biological response pathways. It achieves this through selective H1 receptor blockade, preventing histamine—the key chemical messenger released during an allergy—from binding to its receptors. Loratadine is used for the temporary relief of common allergy symptoms, such as sneezing and a runny nose. This long-acting mechanism providing continuous relief over 24 hours is a key benefit derived from its targeted action.

Regulatory References

  1. Loratadine - StatPearls - NCBI Bookshelf
  2. Loratadine: MedlinePlus Drug Information

What side effects are possible with Loratadim?

Possible Side Effects and Safety Information

The safety profile of medicinal products containing Loratadine (Loratadim) is formally documented in government regulatory texts, which classify adverse reactions based on their frequency and the physiological system affected. This information strictly reflects official prescribing labels and should not be considered medical advice.

Adverse reactions reported in clinical trials and classified as Common (affecting up to 1 in 100 people) include headache, somnolence (drowsiness), fatigue, insomnia, and increased appetite.

Very Rare and Serious Adverse Reactions

Adverse events classified as Very Rare (affecting less than 1 in 10,000 people) have been reported, primarily through post-marketing surveillance, and involve several physiological systems:

  • Immune System: Serious reactions such as hypersensitivity reactions, which include anaphylaxis and angioedema (rapid swelling).
  • Nervous System: Documented effects include dizziness and convulsion (seizures).
  • Cardiac System: Reactions listed are tachycardia (rapid heart rate) and palpitation.
  • Hepatobiliary System: Instances of abnormal hepatic function have been reported.

Reactions such as nausea, dry mouth, rash, and alopecia (hair loss) are also listed under the Very Rare category. Weight increased is noted with a Frequency Not Known.

Safety-Related Constraints

Official labels include specific constraints for use. The medicine must be discontinued at least 48 hours before any skin allergy tests to prevent interference with test results. Furthermore, specific constraints apply to patients with severe hepatic impairment, as reduced drug clearance may necessitate consideration of a lower initial exposure. The safety and efficacy are not established for children younger than two years of age.

Overdose and Emergency Response

Overdose and when to seek help

In the event of ingesting more Loratadim than the labeled dose, regulatory guidance mandates that the patient seek medical help or contact a Poison Control Center right away. This urgent action is required due to the potential for severe or amplified effects beyond normal use.

Documented Clinical Manifestations

Official labeling confirms that overdosage is known to increase the occurrence of anticholinergic symptoms. The specific clinical manifestations of overdose formally documented in regulatory labeling include the central nervous system effects of somnolence (drowsiness) and headache. Cardiovascular effects, such as tachycardia (fast heart rate), are also officially noted. Although rare, significant over-ingestion carries the potential for severe outcomes, including the need for cardiac monitoring and risk of convulsion.

Emergency Procedures and Monitoring

The official guidance confirms that no specific antidote is known for Loratadine. Therefore, treatment involves instituting general symptomatic and supportive measures for management. Procedural steps officially described for managing an acute ingestion include the possible administration of activated charcoal as a slurry with water, or the consideration of gastric lavage by a healthcare professional. Following emergency intervention, medical monitoring of the patient must be continued to observe for persistent effects. It is officially documented that the active substance is not removed by haemodialysis.

Therapeutic Uses of Loratadim

Loratadim is commonly used to help manage symptoms related to allergic conditions. It is applied across domains where additional symptomatic support is needed for conditions involving episodic or fluctuating manifestations, such as seasonal hay fever, perennial allergic rhinitis, and chronic urticaria (hives).

It helps address symptom clusters that may become intense or disruptive, including repetitive sneezing, a runny nose, itchy, watery eyes, and persistent pruritus (itching) of the skin. This use contributes to improved comfort during periods of heightened symptoms. The medication is considered relevant as it offers symptomatic relief that supports control over an extended duration, allowing patients to cope more steadily with symptom fluctuations.

“The profile supports patients during difficult episodes by easing distress and may assist with maintaining functional stability when symptoms become more noticeable.”

This makes it relevant in clinical settings where patients require supportive symptom management and when symptoms are related to physical discomfort.


Quick Fact: Relief for Allergic Discomfort Loratadim is generally used to provide supportive relief for symptoms related to allergic rhinitis (nasal and ocular symptoms) and allergic dermatologic manifestations (hives and itching).

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility to use Loratadim (Loratadine) is governed by official population rules established by regulatory authorities.


Contraindications and Non-Eligibility

Classification Population/Condition
Absolute Contraindication Known hypersensitivity or allergy to Loratadine, its metabolite (desloratadine), or any excipients. Certain formulations containing aspartame are contraindicated for patients with Phenylketonuria (PKU).
Not Recommended Children under 2 years of age, as safety and efficacy have not been established. Use during pregnancy and breastfeeding is also advised against due to the drug and its metabolite passing into breast milk.

Approved and Conditional Use

Loratadim is generally approved for adults and adolescents (age ge 12 years) and children (age 2 or 6 years and older, depending on region and formulation).

Conditional Use: Patients with severe hepatic impairment (severe liver disease) or severe renal impairment must use the medicine with restrictions. Official labeling mandates a modified administration schedule for these populations due to altered drug clearance, ensuring the medicine remains within validated safety parameters.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Loratadine's interaction profile is primarily defined by the way it is processed by the body’s enzymes, particularly the Cytochrome P450 (CYP) system.

Documented Pharmacokinetic Interactions

Specific medicines that inhibit the CYP3A4 and CYP2D6 enzymes have been documented to affect the clearance of loratadine, resulting in increased concentrations of loratadine and its active metabolite in the blood plasma.

Interaction Type Interacting Substances (Examples) Resulting Constraint
Metabolic Inhibition Ketoconazole, Erythromycin, Cimetidine Substantially increased systemic exposure to loratadine.

Other Documented Interactions

The absorption and elimination of loratadine are also affected by food and certain physiological states:

  • Food Effect: Taking loratadine with a meal has been shown to increase the systemic bioavailability (AUC) of the drug.
  • Alcohol: Official studies have shown no potentiation of the effects of alcohol on psychomotor performance when co-administered with loratadine.
  • Population-Specific Considerations: Impaired hepatic function (liver disease) and severe renal impairment significantly reduce the clearance of loratadine and its metabolite, leading to higher plasma levels. This is an important consideration for healthcare providers when assessing appropriate patient intake.

Mechanism of Action

How Loratadine Works


Selective H1 Receptor Modulation

Loratadine primarily exerts its action as a selective inverse agonist of peripheral Histamine H1-receptors. By binding to the H1-receptor, the drug stabilizes the receptor's inactive conformation, functionally blocking the effects of the endogenous mediator, histamine. This molecular interaction directly interrupts the immediate signaling cascade that would otherwise increase vascular permeability and stimulate smooth muscle contraction, resulting in the modulation of downstream cellular effects.


Mediator Release and Pathway Modulation

Beyond its primary receptor-blocking effect, loratadine, along with its active metabolite, engages mechanisms that regulate the intracellular release of inflammatory chemical mediators from immune cells, specifically mast cells and basophils. This process affects systems where specific mediator activity dominates, influencing feedback regulation within the affected cellular pathways, thereby restricting the subsequent supply of mediators. Furthermore, loratadine modifies key intracellular signaling pathways, such as the NF-kappaB pathway, by suppressing the expression of pro-inflammatory factors, modifying early molecular steps that shape systemic physiological outcomes without reference to clinical effects.

Dosage and Administration Information

Loratadim is administered exclusively via the oral route for systemic absorption. It is available in several official formulations, including tablets, syrup, and specialized orally disintegrating tablets (ODT). Administration is generally flexible and may occur with or without food. The use of certain forms, such as orally disintegrating tablets, requires handling with dry hands only to maintain the product's integrity.

Administration Principle Standard Application
Standard Dosing (Adults ge 6 yrs) 10 mg taken once daily
Dosing for Children (2 to 5 yrs) 5 mg taken once daily, usually via syrup/solution. Not established for those under 2 years.
Adjustment for Impairment Dose is reduced to 10 mg every other day for patients with severe hepatic or renal impairment (GFR <30 mL/min).
Handling of Missed Dose If a dose is missed, take it as soon as possible, or skip it entirely if near the next dose; do not double the dose.

The recommended once-daily frequency is central to the regimen, simplifying adherence and providing continuous coverage. This structured approach, including precise dosage adjustments for reduced organ function, ensures the systemic exposure to the drug remains consistent across patient populations.

Recent Clinical Evidence

Loratadim: Recent Clinical Evidence

Recent clinical trials and systematic reviews continue to characterize Loratadim as a second-generation antihistamine primarily studied for its role in managing symptoms related to allergic reactions. Research indicates the drug acts by selectively blocking peripheral H1-receptors, which is associated with mitigating allergic responses such as sneezing, rhinorrhea (runny nose), and ocular symptoms.


Efficacy in Allergic Conditions

Clinical studies, including randomized controlled trials (RCTs), support the use of Loratadim for specific indications:

  • Allergic Rhinitis: Loratadim 10 mg once daily has demonstrated statistically significant improvement in symptoms of seasonal (hay fever) and perennial allergic rhinitis when compared to placebo. It has been evaluated for its effect on symptoms like itching and sneezing.
  • Urticaria (Hives): The medication has been studied for its effectiveness in reducing the symptoms of chronic urticaria, specifically the presence of itchy, raised welts on the skin.

Some research suggests that the clinical benefit may be observed within 75 to 180 minutes of administration, although the reported time-to-onset can vary across studies.


Safety Profile and Comparisons

Loratadim is generally distinguished from first-generation antihistamines due to its lower potential for causing sedation. Trials indicate a low risk of central nervous system effects, with the incidence of drowsiness often reported to be comparable to placebo.

Area of Comparison Key Research Findings
Sedation Low incidence; generally considered non-sedating at recommended doses.
Other Antihistamines Studies comparing Loratadim to certain other second-generation antihistamines often show similar overall efficacy in treating allergic rhinitis symptoms, though rankings of specific symptom relief may vary across meta-analyses.

Key Studies & References

  1. Comparative Effects of Loratadine and Azatadine in the Treatment of Seasonal Allergic Rhinitis
  2. Loratadine - StatPearls (Source for general safety, onset of action, and comparison information)

Frequently Asked Questions (FAQ)

Common questions about Loratadim (FAQ)

Q: Is Loratadim the same type of medicine as Benadryl?

Official information classifies the active ingredient in Loratadim as a second-generation antihistamine. Regulatory documents note that this class of medicine generally has a lower potential for causing sedation compared to first-generation antihistamines, which include the active ingredient in Benadryl (Diphenhydramine).

Q: Do I need a prescription to get Loratadim?

Loratadim is widely available as an Over-The-Counter (OTC) medicine in many regions. This non-prescription status is based on drug approvals from various health authorities and is supported by its established safety profile when used as described in the official documents.

Q: Does Loratadim work better for seasonal allergies or year-round ones?

Clinical studies reviewed by regulatory agencies support the use of Loratadim for treating symptoms related to both seasonal allergies (hay fever) and perennial (year-round) allergic rhinitis. Official evidence indicates a benefit compared to placebo for both indications, but does not state it is superior for one over the other.

Q: Can Loratadim be taken with pain relievers like ibuprofen?

Official drug interaction summaries typically do not indicate a direct pharmacokinetic interaction between Loratadim and general pain relievers like ibuprofen. These summaries focus on interactions that affect how the medicine is processed by the body. The appropriateness of any drug combination must be assessed by a healthcare professional.

Q: Is Loratadim known to interact with caffeine?

Labels for the plain Loratadim product do not typically list caffeine as a direct interaction. However, products combining loratadim with a decongestant (a common combination product) contain a statement that advises reducing caffeine consumption due to potential additive stimulant effects.

Q: Does the strength of Loratadim (e.g., 10 mg) affect how long it works?

The long-acting nature of Loratadim is associated with continuous relief over a 24-hour period. Pharmacokinetic data, which examines how the body handles the drug, indicates that the duration of action is generally independent of the dose over the approved therapeutic range for adults.

Q: Can I take Loratadim every day for a long period?

Loratadim is approved and studied for use in treating symptoms of perennial allergic conditions, which supports continuous daily administration. Official regulatory documents focus on the correct daily frequency but do not usually specify a maximum duration of chronic use.

Q: What are the general safety classifications given to Loratadim by drug agencies?

Drug agencies classify the safety of medicines based on various populations. For example, some authorities, like the Australian TGA, classify loratadine in Pregnancy Category B1, which is a classification based on limited human data. The US FDA has not formally assigned it to a Pregnancy Category.

Q: Can I use Loratadim if I have high blood pressure?

Official labels for the plain Loratadim product do not list high blood pressure (hypertension) as a specific contraindication or major precaution. Users of combination products containing decongestants should note that those labels may carry warnings concerning hypertension.

Q: What is the difference between Loratadim and Claritin?

Claritin is one of the common brand names used to market the active ingredient Loratadine. Loratadim is another trade name containing the exact same active pharmaceutical constituent, Loratadine.

Q: Do studies suggest any potential for dependency with Loratadim?

Loratadim is generally not regulated as a controlled substance by official bodies in most regions. This indicates that regulatory authorities do not classify it as having a recognized potential for abuse or dependency.

Q: Is it true that Loratadim might be less effective for some people over time?

Official regulatory documents and prescribing information do not list reduced effectiveness over time (a concept known as tachyphylaxis) as a known or expected pharmacological effect or warning for loratadine.

Q: Does Loratadim have a known 'rebound effect' when stopped?

Official regulatory labels do not specifically list a 'rebound effect' or withdrawal symptoms upon stopping the medicine. However, the temporary relief provided by the medicine will cease, allowing the underlying allergic symptoms to return.

Q: Is there any difference in how Loratadim works in children versus adults?

While children require a different administration schedule than adults based on age and body weight, the fundamental mechanism of action is considered the same. It works by selectively blocking peripheral H1-receptors across all approved age groups.

Q: Can Loratadim help with symptoms of the common cold, such as a runny nose?

The approved indications for Loratadim are limited to relieving symptoms specifically due to hay fever or other respiratory allergies. Official labels do not approve its use for treating the viral symptoms associated with the common cold.

Q: Are there specific food types that are noted to interact with Loratadim?

Official labeling notes a general food effect that slightly increases the amount of drug absorbed into the body. Unlike some other medicines, specific food items like grapefruit juice are not typically listed as interacting with loratadine.

Q: Are there any known issues with taking Loratadim with vitamins or herbal supplements?

Official information highlights that the combination of any medication with supplements should be assessed by a healthcare professional. Supplements known to cause effects such as drowsiness or dry mouth may intensify these side effects if taken alongside Loratadim.

Q: If I have glaucoma, are there official cautions about using Loratadim?

Official regulatory labels and prescribing information for the plain antihistamine product do not list glaucoma as a specific contraindication or precaution that requires altered use.

Q: How does the onset of action of Loratadim compare to cetirizine, based on research?

Clinical comparison studies indicate that cetirizine's onset of action is generally reported as faster than that of Loratadim. While onset times vary, both medicines are supported by research to be effective for managing allergy symptoms over the 24-hour dosing period.

Q: Are the side effects of Loratadim different for older adults (seniors)?

Official prescribing information generally does not specify a different side effect profile for healthy older adults compared to the general adult population. However, dose adjustment is specifically noted as necessary for all adults with severe kidney or liver impairment.

Q: Is Loratadim described as being compatible with driving or operating machinery?

Regulatory documents require that individuals assess their own response to the medicine before engaging in activities like driving or operating machinery. Although Loratadim is generally considered non-sedating, reports of drowsiness exist, and this caution is included in official product information.

Q: Can Loratadim be taken at night to help with allergy symptoms that disrupt sleep?

Loratadim is taken once daily and provides relief for 24 hours. Since the official label does not mandate a specific time of day for administration, the label permits administration once daily without a required time, allowing the individual to select the most appropriate time for intake.

Q: What evidence exists regarding Loratadim use in people with asthma?

Loratadim is not approved or indicated as a treatment for asthma. However, some clinical studies have explored its potential to reduce allergic symptoms in people who also have asthma, such as in cases of exercise-induced asthma.

Q: What is the highest age group for which Loratadim is studied?

Official safety and efficacy data is established for adults and adolescents (aged ge 12 years) and children (aged ge 2 or 6 years). There is no regulatory upper age limit that mandates specific dosing for healthy senior patients.

Q: Is it safe to assume Loratadim is available worldwide under the same name?

No. The active ingredient is the internationally recognized name Loratadine. However, it is marketed under many different and distinct trade names (such as Claritin, Alavert, etc.) that vary significantly from one country to another.

How should Loratadim be stored and disposed of?

How to Store and Dispose of Loratadine

Loratadine must be stored under controlled conditions to maintain its stability, as required by regulatory labeling.

Storage Requirements

The medicine should be stored at a controlled room temperature, typically 20 C to 25 C (68 F to 77 F), and must be protected from excessive moisture and kept from freezing. It must remain in the container it was dispensed in, kept tightly closed and stored away from heat.

For products like Orally Disintegrating Tablets (ODTs), the medicine must be used immediately upon opening the individual blister. A mandatory regulatory instruction is to Keep out of reach of children.

Disposal Instructions

Unused or expired Loratadine must be disposed of in accordance with local regulations. It is officially recommended to dispose of medicines through community drug take-back programs or by consulting a pharmacist. Do not throw away any medicines via wastewater or household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Loratadim found in:

A-Z Index: